Pharvaris CHAPTER-3 Data: 83% Attack Reduction, All Secondary Endpoints Met
PHVS has more than doubled off its 52-week low of $20.65.
Summary
Pharvaris released detailed CHAPTER-3 Phase 3 data showing deucrictibant XR reduced HAE attack rates by 83% versus placebo with all secondary endpoints met and a clean safety profile.
Key Events · Product Development and Regulatory · PHVS
-
Primary Endpoint Met: 83% Attack Reduction
Deucrictibant XR 40 mg reduced time-normalized HAE attack rate by 83% versus placebo (95% CI: 72-90%, p<0.0001) across all HAE types; 87% reduction in HAE Type 1/2 subgroup.
-
All Secondary Endpoints Statistically Significant
98.2% of patients achieved ≥50% attack reduction, 96.4% achieved ≥70% reduction, 65.5% achieved ≥90% reduction, and 45.5% were attack-free during the 24-week treatment period.
-
Quality of Life Improvement
AE-QoL total score improved by -32.23 points from baseline versus -8.70 for placebo, a -23.53 point difference (p<0.0001).
-
Clean Safety Profile
No treatment-related serious adverse events; only 1.8% SAE rate in treatment arm; 1.8% discontinuation rate due to TEAEs.
Analysis · PHVS · Life Sciences
The detailed CHAPTER-3 data confirms deucrictibant XR's efficacy as a long-term prophylaxis for HAE. The 83% reduction in attack rate versus placebo (p<0.0001) with early onset within one week and sustained effect through 24 weeks positions the drug as a potential best-in-class oral option. All secondary endpoints met statistical significance, including 98.2% of patients achieving ≥50% attack reduction and 45.5% becoming attack-free. The safety profile is clean with no treatment-related serious adverse events. This data supports the planned U.S. NDA submission in 1H2027 and strengthens the company's path to becoming a leader in both on-demand and prophylactic HAE treatment.
How filings like this one have moved
In the 30 days to Sep 8, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHVS was trading at $42.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $20.65 to $38.13. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.